Erythropoietin did not reduce the risk for death or severe disability among infants with hypoxic ischemic encephalopathy ...

Among the most common is neonatal hypoxic-ischemic encephalopathy (HIE), which affects one to three in 1,000 live births per year and accounts for 22% of infant deaths worldwide. Only slightly ...

More information: Natalie H. Chan et al, Neuroprotection for neonatal hypoxic–ischemic encephalopathy: A review of novel therapies evaluated in clinical studies, Developmental Medicine & Child ...

Early onset of severe or moderate neonatal encephalopathy in infants ≥34 wk of gestation *All 3 of the essential criteria are necessary to consider intrapartum hypoxia the etiology of cerebral ...

Neonatal hypoxic-ischemic encephalopathy (HIE) is the most frequent neurologic disease in the perinatal period. Its major cause is oxidative stress, which induces DNA peroxidation and apoptotic ...

Newborns deprived of oxygen have their temperatures lowered to protect against brain damage, but it’s hard to decipher the babies’ immediate response to the intervention. A series of rodent ...

"Hypoxic-ischemic encephalopathy is a leading cause of ... More information: Abstract: Aiming to prevent adverse outcomes of neonatal hypoxic lschemic encephalopathy with erythropoietin - the ...

Neonatal encephalopathy, a condition resulting from perinatal asphyxia, occurs in 2.0–6.0 of every 1000 live births. Without treatment, prognosis is poor and resulting complications such as ...

The Company’s lead candidate, RLS-0071 (pegtarazimod), has received FDA Orphan Drug Designation and Fast Track Designations for hypoxic ischemic encephalopathy (HIE), a devastating disease that ...

To establish if miRNA could serve as diagnostic biomarkers, Kobeissy and his team acquired blood samples from infants who experienced hypoxic stress in utero from the Florida Neonatal Neurologic ...